CEO Executive AssistantAntibody therapy biotechs operate at one of the most technically demanding frontiers of medicine. Whether your company is developing monoclonal antibodies, bispecifics, antibody-drug conjugates, or next-generation antibody formats, the scientific complexity of your platform creates a distinctive leadership challenge. CEOs in this space are often scientists who built the founding platform themselves, which makes releasing technical oversight to their team both essential and psychologically difficult.
The antibody therapy space rewards speed. Competitors move fast, regulatory pathways are complex, and the window for partnership and licensing opportunities can be narrow. A CEO who is embedded in technical operations has no bandwidth for the partnership negotiations, investor relationships, and strategic positioning that determines a biotech’s trajectory.
This delegation framework is designed specifically for the antibody therapy CEO.
The Antibody Therapy CEO’s Dilemma
Most antibody therapy biotech CEOs have scientific backgrounds. They may have founded the company based on their own research, or they may have been recruited as CEO precisely because of their scientific credibility with the platform.
This scientific depth creates a real asset in external credibility. A CEO who can speak with authority about Fc engineering, epitope selection, or bispecific format design is more compelling to academic collaborators, pharma BD teams, and sophisticated investors than a purely managerial executive.
But scientific credibility does not require scientific operational involvement. The CEO who is reviewing antibody screening data, attending CMC team meetings, or managing CRO relationships at the assay level is not providing scientific leadership; they are providing scientific labor. Those are different things.
What Only the CEO Can Do
In an antibody therapy biotech, the CEO’s non-delegable work includes:
- Leading strategic partnership discussions with pharma BD teams
- Representing the company to investors in fundraising and IR activities
- Managing board governance and investor reporting
- Setting platform strategy and target prioritization priorities
- Engaging key opinion leaders and academic collaborators at the senior level
- Managing major licensing negotiations
- Hiring and developing senior scientific and operational leadership
- Setting organizational culture and values
Every hour spent in scientific operations is an hour unavailable for this agenda.
The Delegation Hierarchy for Antibody Therapy Biotechs
Chief Scientific Officer: Owns the research and discovery functions entirely. Antibody design, screening campaigns, hit-to-lead optimization, and in vitro characterization all belong here. The CSO manages the discovery team, sets scientific priorities within the CEO-approved target strategy, and reports to the CEO on portfolio progress.
VP of Biology or Discovery Research Leader: In larger organizations, a VP Biology may own in vitro and in vivo biology while the CSO maintains portfolio-level scientific oversight.
Head of CMC/Bioprocess Development: Owns all chemistry, manufacturing, and controls activities, including cell line development, upstream and downstream process development, analytical development, and manufacturing scale-up. This function requires deep technical expertise and should not require CEO scientific involvement.
VP of Clinical Development or CMO: Owns clinical program strategy, protocol development, CRO selection and management, clinical operations, and regulatory strategy for clinical programs. This is a critical delegation relationship.
Head of Regulatory Affairs: Owns regulatory strategy, agency interactions, IND submissions, and compliance. Must work closely with the CMO but should have clear, independent ownership of regulatory functions.
CFO: Owns financial management, investor reporting infrastructure, and financial planning.
Business Development Director: Manages the pipeline of potential partnerships, coordinates due diligence processes, and prepares materials for CEO-led BD conversations.
Delegating Scientific Portfolio Management
The most important scientific delegation for an antibody therapy CEO is to the CSO. The CSO should own the discovery and research portfolio entirely: which programs are advancing, which are being deprioritized, and what the resource allocation across programs looks like.
The CEO engages in quarterly portfolio reviews where the CSO presents program status, go/no-go decisions, and resource requirements. The CEO sets strategic direction: which disease areas and target classes align with the company’s partnership strategy, and what is the platform’s competitive differentiation hypothesis.
The CEO should not be attending weekly discovery team meetings, reviewing screening data, or approving individual experimental designs. These are CSO-level decisions.
For broader guidance on pharma and biotech CEO delegation, see our pharma CEO delegation guide.
Delegating CMC and Manufacturing
CMC and manufacturing are frequently areas where scientifically trained CEOs stay overly involved. The rationale is that manufacturing quality failures can derail clinical programs. This is true, but CEO involvement in CMC operations does not reduce manufacturing risk; qualified CMC leadership does.
Your Head of CMC should own all manufacturing-related decisions: cell line selection, process development strategy, manufacturing partner selection below a strategic threshold, and analytical method development. The CEO approves major manufacturing commitments (such as a CMO agreement above a defined value), reviews CMC progress in the context of regulatory submissions, and engages when manufacturing issues have strategic implications.
Delegating Clinical Operations
Clinical operations are frequently a source of CEO over-involvement. IND submissions, protocol design, CRO selection, site activation, and clinical monitoring all present natural CEO engagement points. But a strong VP of Clinical Development should own all of these functions.
The CEO reviews the clinical strategy, approves major protocol decisions that have strategic implications (such as a major efficacy endpoint change), and engages with the Board on clinical progress. The CMO and clinical operations team own the execution.
For guidance on structuring clinical operations delegation, see our pharma clinical operations delegation guide.
Business Development Delegation
Partnership negotiations are typically CEO work at the final stages but can be substantially prepared and managed by your BD team in the earlier stages.
Your BD director manages the initial stages of partnership conversations: preparing and distributing the teaser, coordinating NDAs, scheduling introductory meetings, and managing the data room process. The CEO takes over when conversations reach the term sheet or substantive negotiation stage.
This division allows the CEO to focus on the highest-leverage BD moments while keeping the overall partnership pipeline active and moving.
Scientific Advisory Board Management
Scientific advisory boards are a significant credibility and strategic asset for antibody therapy biotechs. Managing SAB relationships is CEO work at the relationship level but administrative work at the logistics level.
Your executive assistant or research program manager should own SAB meeting logistics: scheduling, agenda preparation, travel coordination, and follow-up documentation. The CEO owns the SAB relationships, facilitates the strategic scientific discussions at SAB meetings, and ensures SAB members are appropriately recognized and engaged.
Building Delegation Confidence
A common pattern in biotech CEOs is what might be called the delegation anxiety cycle: the CEO delegates, something goes differently than expected, the CEO takes back control, and the team learns that delegation is not real. Breaking this cycle requires tolerance for different approaches and explicit retrospective learning when things go wrong.
When a delegated task produces a suboptimal result, the right response is to diagnose the delegation failure (was the outcome unclear? was the authority insufficient? was there a skill gap?) and fix the system, not to reassert personal control. Teams that learn from delegation failures build more resilient capability over time.
Measuring Delegation Effectiveness
Track quarterly:
- CEO time in investor/BD/strategic work versus scientific operations
- Pipeline program progression velocity
- CMC milestone achievement rates
- Clinical enrollment and operational metrics
- BD pipeline activity and partnership discussions in progress
- Leadership team retention and capability growth
Conclusion
Antibody therapy biotech leadership requires scientific credibility and strategic bandwidth simultaneously. The delegation framework described here enables CEOs to maintain genuine scientific authority through portfolio strategy and senior scientific relationships while trusting a capable team to execute the technical work that advances the pipeline.
As Harvard Business Review research on biotech leadership has noted, the most effective biotech CEOs are those who leverage their scientific backgrounds for external credibility and strategic direction while building the operational teams that drive execution. Delegation is the mechanism that makes both possible.
Build the team. Define the authority. Create the oversight structures. And invest your scientific credibility where it creates the most strategic leverage.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.